Von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney Cancer

American Journal of Nephrology

Volumn 24, Issue 1, 2004, Pages 1-13

  Maynard, Mindy A ^a   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; E3 ubiquitin ligase; Hypoxia; Hypoxia inducible factor; Renal clear cell carcinoma; Von Hippel Lindau disease; Von Hippel Lindau tumor suppressor protein

Indexed keywords

DNA; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOENZYME; MATRIX METALLOPROTEINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN SUBUNIT; TISSUE INHIBITOR OF METALLOPROTEINASE; UBIQUITIN PROTEIN LIGASE; VON HIPPEL LINDAU PROTEIN;

ASSOCIATION; CARCINOGENESIS; CELL CYCLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; DIMERIZATION; DNA BINDING; EXTRACELLULAR MATRIX; FAMILIAL CANCER; GENETIC TRANSCRIPTION; HUMAN; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION; VON HIPPEL LINDAU DISEASE;

ADENOCARCINOMA, CLEAR CELL; CLINICAL TRIALS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 1342301598     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075346     Document Type: Review

References (152)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. JAMA 1995;273:564-570.
3. Walther M, Lubensky I, Venzon D, Zbar B, Linehan W: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 1995;154:2010-2014.
4. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149:2089-2094.
5. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
6. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-9704.
7. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS: Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-595.
8. Zbar B, Brauch H, Talmadge C, Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987;327:721-724.
9. Kovacs G, Brusa P, De Riese W: Tissue-specific expression of a constitutional 3;6 translocation: Development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989;43:422-427.
10. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM: Hereditary renal cancers. Radiology 2003;226:33-46.
11. Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, Cheadle JP: Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer 2001;85:1226-1230.
12. Krymskaya VP: Tumour suppressors hamartin and tuberin: Intracellular signalling. Cell Signal 2003;15:729-739.
13. Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
14. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410.
15. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA: A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202.
16. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002;2:157-164.
17. Davis CJ Jr, Mostofi FK, Sesterhenn IA: Renal medullary carcinoma: The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
18. Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ: Renal medullary carcinoma: Clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 2002;60:1083-1089.
19. Lynch HT, Smyrk T: Hereditary nonpolyposis colorectal cancer (Lynch syndrome): An updated review. Cancer 1996;78:1149-1167.
20. Lynch HT, Lynch JF: Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 2000;18:305-313.
21. Maher E, Kaelin WG: Von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-391.
22. Iliopoulos O, Kaelin WG: Von Hippel-Lindau disease; in Fisher DE (ed): Hereditary Cancer. Clifton, Humana Press, 2000.
23. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
24. Maher ER, Webster AR, Moore AT: Clinical features and molecular genetics of von Hippel-Lindau disease. Ophthalmic Genet 1995;16:79-84.
25. Ivan M, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001;11:27-34.
26. Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER: Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med 1998;243:527-533.
27. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH: Von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
28. Leung SK, Ohh M: Playing tag with HIF: The VHL story. J Biomed Biotechnol 2002;2:131-135.
29. Kondo K, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-125.
30. Stolle C, Glenn G, Zbar B, Humphrey J, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan W: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
31. Ohh M, Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein: New perspectives. Mol Med Today 1999;5:257-263.
32. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum Mutat 1995;5:66-75.
33. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, et al: Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-357.
34. Kaelin WG Jr: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
35. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D, et al: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-269.
36. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
37. Renbaum P, Duh FM, Latif F, Zbar B, Lerman M, Kuzmin I: Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene. Hum Genet 1996;98:666-671.
38. Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, Maher ER: Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. J Med Genet 2002;39:463-472.
39. Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998;95:8817-8822.
40. Iliopoulos O, Ohh M, Kaelin W: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-11666.
41. Blankenship C, Naglich J, Whaley J, Seizinger B, Kley N: Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-1535.
42. Iliopoulos O, Kibel A, Gray S, Kaelin WG: Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-826.
43. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-1308.
44. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc Natl Acad Sci USA 1996;93:10589-10594.
45. Kessler P, Vasavada S, Rackley R, Stackhouse T, Duh F, Latif F, Lerman M, Zbar B, Williams B: Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1995;1:457-466.
46. Richards F, Schofield P, Fleming S, Maher E: Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-644.
47. Gnarra J, Ward J, Porter F, Wagner J, Devor D, Grinberg A, Emmert-Buck M, Westphal H, Klausner R, Linehan W: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997;94:9102-9107.
48. Haase VH, Glickman JN, Socolovsky M, Jaenisch R: Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001;98:1583-1588.
49. Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky I, Linehan W, et al: Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998;58:504-508.
50. Vortmeyer A, Gnarra J, Emmert-Buck M, Katz D, Linehan W, Oldfield E, Zhuang Z: Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997;28:540-543.
51. Lach B, Gregor A, Rippstein P, Omulecka A: Angiogenic histogenesis of stromal cells in hemangioblastoma: Ultrastructural and immunohistochemical study. Ultrastruct Pathol 1999;23:299-310.
52. Corless CL, Kibel A, Iliopoulos O, Kaelin WG Jr: Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum Pathol 1997;28:459-464.
53. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE: Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996;75:231-238.
54. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
55. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD: The von Hippel-Lindau tumor suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997;94:2156-2161.
56. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, Gutierrez MD, Garcia-Pardo A, Sanchez-Madrid F, Landazuri MO: Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 2002;62:2929-2936.
57. Shiao YH, Resau JH, Nagashima K, Anderson LM, Ramakrishna G: The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res 2000;60:2816-2819.
58. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr: Binding of the von Hippel-Lindau tumor suppressor protein to elongins B and C. Science 1995;269:1444-1446.
59. Duan DR, Pause A, Burgess W, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 1995;269:1402-1406.
60. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr: Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-741.
61. Deshaies R: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999;15:435-467.
62. Ciechanover A, Orian A, Schwartz AL: Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 2000;22:442-451.
63. Pause A, Peterson B, Schaffar G, Stearman R, Klausner R: Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 1999;96:9533-9538.
64. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, et al: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-661.
65. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B: Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 1995;55:4544-4548.
66. Ohta T, Michel JJ, Schottelius AJ, Xiaong Y: ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999;3:535-541.
67. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan ZQ: Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of 1RBBB. Mol Cell 1999;3:527-533.
68. Skowyra D, Koepp DM, Kamura T, Conrad MN, Conaway RC, Conaway JW, Elledge SJ, Harper JW: Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science 1999;284:662-665.
69. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ: SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996;86:263-274.
70. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-elonginC-elonginB complex: Implications for VHL tumor suppressor function. Science 1999;284:455-461.
71. Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG Jr, Welch WJ: Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol 2002;22:1947-1960.
72. Ohh M, Takagi Y, Aso T, Stebbins C, Pavletich N, Zbar B, Conaway R, Conaway J, Kaelin W Jr: Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 1999;104:1583-1591.
73. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Chau V, Kaelin WG Jr: Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain. Nat Cell Biol 2000;2:423-427.
74. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-578.
75. Semenza G: Perspectives on oxygen sensing. Cell 1999;98:281-284.
76. Wenger R: Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 2000;203:1253-1263.
77. Zhu H, Bunn F: Oxygen sensing and signaling: Impact on the regulation of physiologically important genes. Respir Physiol 1999;115:239-247.
78. Wiener CM, Booth G, Semenza GL: In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 1996;225:485-488.
79. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, Perdew GH, Bradfield CA: Characterization of a subset of the basic-helix-loop-helix- PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997;272:8581-8593.
80. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, et al: HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-657.
81. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, et al: Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998;92:2260-2268.
82. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Fujii-Kuriyama Y: Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999;18:1905-1914.
83. Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
84. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-4278.
85. Peng J, Zhang L, Drysdale L, Fong GH: The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci USA 2000;97:8386-8391.
86. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M: Multiple splice variants of the human HIF-3alpha locus are targets of the VHL E3 ubiquitin ligase complex. J Biol Chem 2003;278:11032-11040.
87. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L: Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002;277:32405-32408.
88. Wang GL, Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-1237.
89. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N: Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001;287:808-813.
90. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA: Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-213.
91. 2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus [letter; comment]. Cell 2001;107:1-3.
92. Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, Saijo Y, Gotoh O, Sogawa K, Fujii-Kuriyama Y: cDNA cloning and tissue-specific expression of a novel basic helix-loophelix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996;16:1706-1713.
93. Takahata S, Sogawa K, Kobayashi A, Ema M, Mimura J, Ozaki N, Fujii-Kuriyama Y: Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1α, HLF, and clock. Biochem Biophys Res Commun 1998;248:789-794.
94. Cockman M, Masson N, Mole D, Jaakkola P, Chang G, Clifford S, Maher E, Pugh C, Ratcliffe P, Maxwell P: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741.
95. Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298-4309.
96. Sutter C, Laughner E, Semenza G: Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 2000;97:4748-4753.
97. Kallio P, Wilson W, O'Brien S, Makino Y, Poellinger L: Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-6525.
98. Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-22647.
99. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-7992.
100. Srinivas V, Zhang L, Zhu X, Caro J: Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 1999;260:557-561.
101. O'Rourke J, Tian YM, Ratcliffe PJ, Pugh CW: Oxygen-regulated and transactivation domains in endothelial PAS protein 1: Comparison with hypoxia-inducible factor-1α. J Biol Chem 1999;274:2060-2071.
102. 2 sensing. Science 2001;292:464-468.
103. 2-regulated prolyl hydroxylation. Science 2001;292:468-472.
104. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-5206.
105. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation [see comments]. Cell 2001;107:43-54.
106. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-1340.
107. Huang J, Zhao Q, Mooney SM, Lee FS: Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 2002;277:39792-39800.
108. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C: Hypoxia up-regulates prolyl hydroxylase activity: A feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 2003;278:38183-38187.
109. Pugh C, O'Rourke J, Nagao M, Gleadle J, Ratcliffe P: Activation of hypoxia-inducible factor-1: Definition of regulatory domains within the alpha subunit. J Biol Chem 1997;272:11205-11214.
110. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L: Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998;17:6573-6586.
111. Carrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H, Poellinger L: Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 2000;20:402-415.
112. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM: An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996;93:12969-12973.
113. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-861.
114. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL: Transactivation and inhibitory domains of hypoxia-inducible factor 1α. J Biol Chem 1997;272:19253-19260.
115. Luo JC, Shibuya M: A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha). Oncogene 2001;20:1435-1444.
116. Ikuta T, Eguchi H, Tachibana T, Yoneda Y, Kawajiri K: Nuclear localization and export signals of the human aryl hydrocarbon receptor. J Biol Chem 1998;273:2895-2904.
117. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, et al: Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003;278:7520-7530.
118. Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, Czyzyk-Krzeska MF: Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem 2003;85:483-491.
119. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L: Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-554.
120. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, et al: Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-2961.
121. Maxwell P, Weisner M, Chang GW, Clifford S, Vaux E, Pugh C, Maher E, Ratcliffe P: The von Hippel-Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor α subunits. Nature 1999;399:271-275.
122. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158.
123. Nguyen-Vu PA, Fackler I, Rust A, DeClue JE, Sander CA, Volkenandt M, Flaig M, Yeung RS, Wienecke R: Loss of tuberin, the tuberous-sclerosis-complex- 2 gene product is associated with angiogenesis. J Cutan Pathol 2001;28:470-475.
124. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, Lee S: Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387-1392.
125. Knebelmann B, Ananth S, Cohen H, Sukhatme V: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-231.
126. Humes H, Beals T, Cieslinski D, Sanchez I, Page T: Effects of transforming growth factor-beta, transforming growth factor-alpha, and other growth factors on renal proximal tubule cells. Lab Invest 1991;64:538-545.
127. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD: The contribution of VHL substrate binding and HIF1-T to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-255.
128. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-246.
129. Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, Kishida T, Kaneko S, Yao M, Ohno S, et al: Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-497.
130. Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G: Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2002;277:4656-4662.
131. Kuznetsova AV, Meller J, Schnell PO, Nash JA, Ignacak ML, Sanchez Y, Conaway JW, Conaway RC, Czyzyk-Krzeska MF: Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 2003;100:2706-2711.
132. Na X, Duan HO, Messing EW, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, Wu G: Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003;22:4249-4259.
133. Hynes R: Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 1992;69:11-25.
134. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr: Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-1027.
135. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R: Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998;58:4957-4962.
136. Koochekpour S, Jeffers M, Wang P, Gong C, Taylor G, Roessler L, Stearman R, Vasselli J, Stetler-Stevenson W, Kaelin W Jr, et al: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-5912.
137. Cohen H, Zhou M, Welsh A, Zarghamee S, Scholz H, Mukhopadhyay D, Kishida T, Zbar B, Knebelmann B, Sukhatme V: An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 1999;266:43-50.
138. Rafty LA, Khachigian LM: Von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. J Cell Biochem 2002;85:490-495.
139. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G: The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J 2003;22:1857-1867.
140. Kim SS, Chen YM, O'Leary E, Witzgall R, Vidal M, Bonventre JV: A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc Natl Acad Sci USA 1996;93:15299-15304.
141. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG, Rauscher F Jr: KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 1996;10:2067-2078.
142. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP, Schaffner W: Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res 1996;24:4859-4867.
143. Underhill C, Qutob MS, Yee SP, Torchia J: A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J Biol Chem 2000;275:40463-40470.
144. Lechner MS, Begg GE, Speicher DW, Rauscher FJ 3rd: Molecular determinants for targeting heterochromatin protein 1-mediated gene silencing: Direct chromoshadow domain-KAP-1 corepressor interaction is essential. Mol Cell Biol 2000;20:6449-6465.
145. van den Berg A, Dijkhuizen T, Draaijers TG, Hulsbeek MM, Maher ER, van den Berg E, Storkel S, Buys CH: Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer 1997;19:228-232.
146. Semenza GL: HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480.
147. Maxwell PH, Pugh CW, Ratcliffe PJ: Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293-299.
148. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER: Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002;62:3803-3811.
149. Pause A, Lee S, Lonergan KM, Klausner RD: The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998;95:993-998.
150. Kim M, Katayose Y, Li Q, Rakkar A, Li Z, Hwang S, Katayose D, Trepel J, Cowan K, Seth P: Recombinant adenovirus expressing von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem Biophys Res Commun 1998;253:672-677.
151. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD: VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002;62:3014-3019.
152. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W: Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.